Navigation Links
OncoSec to Present at 10th Annual BioPartnering North America

SAN DIEGO, Feb. 24, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that Punit Dhillon, President and CEO at OncoSec, will be presenting at the 10th Annual BioPartnering North America in Vancouver, Canada, February 26-28, 2012.


10th Annual BioPartnering North America

Vancouver Convention Centre

1055 Canada Place

Vancouver, BC, V6C 0C3, Canada

February 26-28, 2012


OncoSec Presentation

February 28, 2012

10:30am PT

The 10th Annual BioPartnering North America is a conference held in the Pacific Rim tapping into the fourth largest biotech cluster in the world. It attracts life science professionals from across the globe with the aim of building close ties between industry leaders. Past attendance has seen delegates from the United States, Canada, Europe, Japan, Korea as well as China and is expected to continue to grow in diversity.

To arrange a meeting with management please contact Adam Holdsworth,

The Investor Relations Group 212-285-3210

About OncoSec Medical Inc.

OncoSec Medical Incorporated is a biopharmaceutical company developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic disease. OMS ElectroOncology therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives.  OncoSec's core technology is based upon its proprietary use of an electroporation platform, the OncoSec Medical System (OMS), to dramatically enhance the delivery and uptake of a locally delivered DNA-based immuno-cytokine (OMS ElectroImmunotherapy) or chemotherapeutic agents (OMS ElectroChemotherapy). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy targeting lethal skin cancers. More information is available at Additional information may also be found at OncoSec's Facebook, Twitter, and LinkedIn sites.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


SOURCE OncoSec Medical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. OncoSec Medical Appoints Punit Dhillon as President and CEO
2. OncoSec Medical Featured in Medical Device Daily
3. OncoSec Announces Leadership Team Appointments
4. OncoSec Announces Clinical Leadership Appointments
5. OncoSec Medical Reports Third Quarter 2011 Financial Results
6. InterMune to Present at Canaccord Adams Conference
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
8. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
10. Bionovo to Present at Canaccord Adams Global Growth Conference
11. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
Post Your Comments:
(Date:12/1/2015)... 2015 Researchers at the Broad Institute of ... Research at MIT have engineered changes to the revolutionary ... "off-target" editing errors. The refined technique addresses one of ... editing. Science , Feng Zhang ... approximately 1,400 amino acids that make up the Cas9 ...
(Date:12/1/2015)... , Dec. 1, 2015  The Minnesota High ... of the 2015 Tekne Award in the Small and ... at the Minneapolis Convention Center, ... played a significant role in developing new technologies that ... around the world. Clostridium difficile infection ...
(Date:12/1/2015)... Frederick, MD (PRWEB) , ... December 01, 2015 ... ... management solutions provider, announces that its best selling system laboratory animal colony management ... ezColony® Cloud today, without investing in on-site IT resources., , ...
(Date:12/1/2015)... Dr. Harry Lander , President of Regen, expands his role to ... and recruits five distinguished scientists to join ... expands his role to include serving as ... scientists to join advisory team --> Dr. Harry ... serving as Chief Science Officer and ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, Inc., ... U.S. distribution of its DNA library preparation products, ... Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has ... preparation of NGS libraries for liquid biopsies--the analysis ... and prognostic applications in cancer and other conditions. ...
(Date:10/29/2015)... , Oct. 29, 2015 Today, ... a partnership with 2XU, a global leader in ... a smart hat with advanced bio-sensing technology. The ... athletes to monitor key biometrics to improve overall ... partnership, the two companies will bring together the most ...
(Date:10/27/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), the ... has adopted the Synaptics ® ClearPad ® ... its newest flagship smartphones, the Nexus 5X by LG ... --> --> Synaptics works closely ... collaboration in the joint development of next generation technologies. ...
Breaking Biology News(10 mins):